As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Lenz Therapeutics Inc. The largest reported stake is BML Investment Partners, L.P.'s, at 6.7%. 21 filings are on record since July 14, 2025 (Schedule 13G, November 4, 2026).
Sell to companies like Lenz Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 611,575 · Shared voting: 0 · Sole dispositive: 613,374 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: BML Investment Partners, L.P. · Sole voting: 0 · Shared voting: 2,110,727 · Sole dispositive: 0 · Shared dispositive: 2,110,727 · SCHEDULE 13G, 2026-11-04
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 70,533 · Sole dispositive: 0 · Shared dispositive: 70,533 · SCHEDULE 13D/A, 2026-11-02
- · Reporting person: BlackRock Portfolio Management LLC · Sole voting: 1,395,487 · Shared voting: 0 · Sole dispositive: 1,645,489 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: Millennium Management LLC · Sole voting: 0 · Shared voting: 1,159,987 · Sole dispositive: 0 · Shared dispositive: 1,159,987 · SCHEDULE 13G/A, 2026-10-21
Lenz Therapeutics Inc has 21 Schedule 13D or 13G filings on record since 2025-07-14. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: about 40 jobs, latest 2026-10-28 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 6.7% | 2,110,727 | SCHEDULE 13G, 2026-11-04 | 2026-11-02 |
| BlackRock, Inc. | 5.8% | 1,804,099 | SCHEDULE 13G, 2026-04-27 | 2026-03-31 |
| BlackRock Portfolio Management LLC | 5.2% | 1,645,489 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Squarepoint Ops LLC | 5.1% | 1,593,246 | SCHEDULE 13G, 2026-04-08 | 2026-04-01 |
| 4.8% | 1,357,751 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 | |
| Paradigm BioCapital Advisors LP | 3.8% | 1,073,461 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Millennium Management LLC | 3.7% | 1,159,987 | SCHEDULE 13G/A, 2026-10-21 | 2026-09-30 |
| Versant Venture Capital VI, L.P. | 3.4% | 1,050,599 | SCHEDULE 13D/A, 2025-11-10 | 2025-11-05 |
| Fmr LLC | 2% | 613,374 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| RA Capital Management, L.P. | 0.2% | 70,533 | SCHEDULE 13D/A, 2026-11-02 | 2026-10-29 |
| Ridgeback Capital Investments L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Lenz Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Lenz Therapeutics Inc and the records around it.
Lenz Therapeutics Inc elsewhere on the record
- Layoff notices Oct 2026
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Squarepoint Ops LLC also filed stake reports on 1 other company: Cartesian Therapeutics, Inc. (Mar 2026)
- Ridgeback Capital Investments L.P. also filed stake reports on 3 other companies: Replimune Group, Inc. (Aug 2026), iTeos Therapeutics, Inc. (Nov 2025), Semler Scientific, Inc. (Nov 2025)
- Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies: Tempest Therapeutics, Inc. (Apr 2026), Monte Rosa Therapeutics, Inc. (Jan 2026), LAVA Therapeutics N.V. (Sep 2025)
Watch Lenz Therapeutics Inc
Get an email when Lenz Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lenz Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lenz Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lenz Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
23 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 0 | 2,110,727 | 0 | 2,110,727 | SCHEDULE 13G, 2026-11-04 |
| BlackRock Portfolio Management LLC | 1,395,487 | 0 | 1,645,489 | 0 | SCHEDULE 13G, 2026-10-27 |
| Millennium Management LLC | 0 | 1,159,987 | 0 | 1,159,987 | SCHEDULE 13G/A, 2026-10-21 |
| Millennium Group Management LLC | 0 | 1,159,987 | 0 | 1,159,987 | SCHEDULE 13G/A, 2026-10-21 |
| Israel A. Englander | 0 | 1,159,987 | 0 | 1,159,987 | SCHEDULE 13G/A, 2026-10-21 |
| Fmr LLC | 611,575 | 0 | 613,374 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 613,374 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| RA Capital Management, L.P. | 0 | 70,533 | 0 | 70,533 | SCHEDULE 13D/A, 2026-11-02 |
| Peter Kolchinsky | 0 | 70,533 | 0 | 70,533 | SCHEDULE 13D/A, 2026-11-02 |
| Rajeev Shah | 0 | 70,533 | 0 | 70,533 | SCHEDULE 13D/A, 2026-11-02 |
| RA Capital Healthcare Fund, L.P. | 0 | 54,582 | 0 | 54,582 | SCHEDULE 13D/A, 2026-11-02 |
The latest filing identifies Lenz Therapeutics Inc by CUSIP 52635N103 and gives its principal executive office as 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA 92075 (SCHEDULE 13G/A, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-14 | Versant Venture Capital VI, L.P. | 5.6% | SCHEDULE 13D/A |
| 2025-08-20 | Versant Venture Capital VI, L.P. | 4.9% | SCHEDULE 13D/A |
| 2025-09-22 | Versant Venture Capital VI, L.P. | 4.1% | SCHEDULE 13D/A |
| 2025-10-17 | BlackRock, Inc. | 5.1% | SCHEDULE 13G |
| 2025-11-07 | Fmr LLC | 15% | SCHEDULE 13G |
| 2025-11-07 | RA Capital Management, L.P. | 13.6% | SCHEDULE 13D/A |
| 2025-11-10 | Versant Venture Capital VI, L.P. | 3.4% | SCHEDULE 13D/A |
| 2025-11-14 | Steven A. Cohen | 4.8% | SCHEDULE 13G/A |
| 2025-11-14 | Paradigm BioCapital Advisors LP | 3.8% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 4.9% | SCHEDULE 13G/A |
| 2026-02-05 | Fmr LLC | 11.8% | SCHEDULE 13G/A |
| 2026-02-17 | Ridgeback Capital Investments L.P. | 0% | SCHEDULE 13G/A |
| 2026-04-08 | Squarepoint Ops LLC | 5.1% | SCHEDULE 13G |
| 2026-04-27 | BlackRock, Inc. | 5.8% | SCHEDULE 13G |
| 2026-06-26 | Millennium Management LLC | 5.1% | SCHEDULE 13G |
| 2026-09-08 | Fmr LLC | 5.7% | SCHEDULE 13G/A |
| 2026-10-21 | Millennium Management LLC | 3.7% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock Portfolio Management LLC | 5.2% | SCHEDULE 13G |
| 2026-11-02 | RA Capital Management, L.P. | 0.2% | SCHEDULE 13D/A |
| 2026-11-04 | BML Investment Partners, L.P. | 6.7% | SCHEDULE 13G |
| 2026-11-05 | Fmr LLC | 2% | SCHEDULE 13G/A |
Questions about who owns Lenz Therapeutics Inc
Who owns Lenz Therapeutics Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Lenz Therapeutics Inc: BML Investment Partners, L.P. (6.7%, Schedule 13G, filed 2026-11-04), BlackRock, Inc. (5.8%, Schedule 13G, filed 2026-04-27), BlackRock Portfolio Management LLC (5.2%, Schedule 13G, filed 2026-10-27) and Squarepoint Ops LLC (5.1%, Schedule 13G, filed 2026-04-08).
Who are the largest shareholders of Lenz Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Lenz Therapeutics Inc on this page are BML Investment Partners, L.P. (6.7%), BlackRock, Inc. (5.8%) and BlackRock Portfolio Management LLC (5.2%).
When did BML Investment Partners, L.P. buy into Lenz Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from BML Investment Partners, L.P. on this page is the Schedule 13G, filed 2026-11-04, reporting 6.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 21 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Lenz Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Leadership change: Daniel Chevallard appointed, President | — | Leadership changes | Source |
| July 2, 2026 | Leadership change: Zach Scheiner departs | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Lenz Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.